The Front Room — a clinical regulatory commons
RSS
← Back to The Docket
JUL 8 2026
APPROVED · 83 DAYS AGO

Vera Therapeutics, Inc. — Trutakna (atacicept-vymj) $VERA

for primary IgA nephropathy

NDA

FDA granted accelerated approval to Trutakna (atacicept-vymj) for adult patients with primary IgA nephropathy.

About

IgA nephropathy is a kidney and immune-system disease in which inflammation damages the glomeruli, the tiny filtering units that clean the blood, and aggressive cases can also attack organs such as the liver, skin, and heart. Trutakna (atacicept-vymj) is a lab-made protein that binds and blocks two immune signals, BLyS and APRIL, that tell B cells to multiply and produce antibodies. Because IgA nephropathy is driven by faulty antibody buildup in the kidney, quieting those B cells could reduce that supply at its source and may help slow the kidney damage.